Acute myelogenous leukemia (AML) is characterized by the uncontrolled growth of tumor cells in the bone marrow. Standard treatment includes induction remission therapy followed by several courses of consolidation chemotherapy. The 5‐year disease‐free survival rate is only 39%. A 61‐year‐old man with AML achieved remission after standard induction therapy but experienced severe myelosuppression and a serious infection, leaving him too exhausted for further chemotherapy. Remarkably, he remained in remission for over 5 years. This case suggests that both the initial chemotherapy and the immune response triggered by severe infection may have contributed to long‐term remission.
Motoharu Shibusawa (Thu,) studied this question.